Clinical Trials in Detroit

Showing 1721-1740 of 9,449 trials

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

NCT04878432

The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).

Myelodysplastic Syndrome (MDS)

Novartis Pharmaceuticals39 participantsStarted Mar 2022

Phoenix, Arizona, United States • Tucson, Arizona, United States • Denver, Colorado, United States +12 more locations

COMPLETED< 1 mile

SUBLOCADE Long-term Outcomes

NCT05860959

This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Long-term patterns of abstinence/opioid misuse as well as measures of participants' physical, psychological, social, and economic well-being will be monitored to better understand factors associated with recovery from opioid use disorder (OUD). Therefore, this study will observe participants up to a maximum of 4 years.

Opioid Use Disorder

Indivior Inc.480 participantsStarted Aug 2023

Costa Mesa, California, United States • Escondido, California, United States • Westport, Connecticut, United States +46 more locations

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

SUBLOCADE Long-term Outcomes

Find Trials by Condition in Detroit

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

Longitudinal Study of Mitochondrial Hepatopathies

Biliary Atresia Study in Infants and Children

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

A Study of LY3841136 in Overweight and Obese Participants

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia